We're a highly collaborative group passionate about using synthetic immunology to advance adoptive cell therapies.
Chimeric Antigen Receptor (CAR) T cells are a promising cellular immunotherapeutic strategy for a wide variety of cancers. Despite remarkable clinical results against some types of hematological malignancies, several key therapeutic challenges currently confine the successful use of this powerful therapy to a few limited contexts.
Our laboratory is aimed at understanding the current limitations of CAR T cell therapy using innovative tumor models and functional genomics and overcoming these challenges by reprogramming T cells with the use of genome editing and synthetic receptors.
Immunobiology of CAR T Cells in Solid Tumors
We are developing tumor models recapitulating a complex immunosuppressive microenvironment to understand the factors limiting CAR T cells in solid tumors.
High Throughput Tool Development for Accelerated CAR Engineering
We are using a gene editing and multiparametric single-cell analysis platform to accelerate the discovery of CARs with novel functions
Improvement of Gene-Edited Immune Cell Manufacturing for Clinical Trials
We are collaborating with multiple labs at UCSF to establish a gene-edited immune cell clinical platform
Support Eyquem Lab
If you are excited about our research and would like to support it through a philanthropic gift, please let us know.